Crystal structure of the HIV-1 integrase core domain in complex with sucrose reveals details of an allosteric inhibitory binding site

FEBS Letters

Volumn 584, Issue 8, 2010, Pages 1455-1462

  Wielens, Jerome ^a,b   Headey, Stephen J ^a   Jeevarajah, Dharshini ^c   Rhodes, David I ^c   Deadman, John ^c   Chalmers, David K ^a   Scanlon, Martin J ^a   Parker, Michael W ^b,d  

^a MONASH UNIVERSITY   (Australia)

^b ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c Avexa Ltd   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Anti HIV drug; HIV 1 integrase; Ligand binding; X ray crystallography

Indexed keywords

INTEGRASE; INTEGRASE INHIBITOR; SUCROSE;

ALLOSTERISM; ARTICLE; BINDING SITE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; ENZYME STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN DOMAIN;

ALLOSTERIC REGULATION; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; GLYCEROL; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, TERTIARY; SUCROSE; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77951294949     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2010.03.016     Document Type: Article

References (78)

1. Brown P.O. Integration. Retroviruses 1997, 161-201. Cold Spring harbour Press, Plainview, NY. J.M. Coffin, S.H. Hughes, H.E. Varmus (Eds.).
2. Guiot E., et al. Relationship between the oligomeric status of HIV-1 integrase on DNA and enzymatic activity. J. Biol. Chem. 2006, 281:22707-22719.
3. Vandegraaff N., Engelman A. Molecular mechanisms of HIV integration and therapeutic intervention. Expert Rev. Mol. Med. 2007, 9:1-19.
4. Summa V., et al. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J. Med. Chem. 2008, 51:5843-5855.
5. Chirch L.M., Morrison S., Steigbigel R.T. Treatment of HIV infection with raltegravir. Expert Opin. Pharmacother. 2009, 10:1203-1211.
6. Imaz A., Del Saz S.V., Ribas M.A., Curran A., Caballero E., Falco V., Crespo M., Ocana I., Diaz M., Gopegui E.R., Riera M., Ribera E. Raltegravir, Etravirine, and Ritonavir-Boosted Darunavir: A Safe and Successful Rescue Regimen for Multidrug-Resistant HIV-1 Infection. J Acquir Immune Defic Syndr 2009, 52:382-386.
7. Garvey E.P., Schwartz B., Gartland M.J., Lang S., Halsey W., Sathe G., Carter H.L., Weaver K.L. Potent inhibitors of HIV-1 integrase display a two-step, slow-binding inhibition mechanism which is absent in a drug-resistant T66I/M154I mutant. Biochemistry 2009, 48:1644-1653.
8. Marinello J., Marchand C., Mott B.T., Bain A., Thomas C.J., Pommier Y. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry 2008, 47:9345-9354.
9. Walker M.A. New approaches for inhibiting HIV integrase: a journey beyond the active site. Curr. Opin. Investig. Drugs 2009, 10:129-136.
10. Al-Mawsawi L.Q., Fikkert V., Dayam R., Witvrouw M., Burke T., Borchers C.H., Neamati N. Discovery of a small-molecule HIV-1 integrase inhibitor-binding site. Proc. Natl. Acad. Sci. USA 2006, 103:10080-10085.
11. Busschots K., De Rijck J., Christ F., Debyser Z. In search of small molecules blocking interactions between HIV proteins and intracellular cofactors. Mol. Biosyst. 2009, 5:21-31.
12. Du L., Zhao Y.X., Yang L.M., Zheng Y.T., Tang Y., Shen X., Jiang H.L. Symmetrical 1-pyrrolidineacetamide showing anti-HIV activity through a new binding site on HIV-1 integrase. Acta Pharmacol. Sin. 2008, 29:1261-1267.
13. Kessl J.J., Eidahl J.O., Shkriabai N., Zhao Z., McKee C.J., Hess S., Burke T.R., Kvaratskhelia M. An allosteric mechanism for inhibiting HIV-1 integrase with a small molecule. Mol. Pharmacol. 2009, 76:824-832.
14. Shkriabai N., Patil S.S., Hess S., Budihas S.R., Craigie R., Burke T.R., Le Grice S.F., Kvaratskhelia M. Identification of an inhibitor-binding site to HIV-1 integrase with affinity acetylation and mass spectrometry. Proc. Natl. Acad. Sci. USA 2004, 101:6894-6899.
15. de Bethune M.P. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). Antiviral Res. 2010, 85:75-90.
16. Dyda F., Hickman A.B., Jenkins T.M., Engelman A., Craigie R., Davies D.R. Crystal structure of the catalytic domain of HIV-1 integrase - similarity to other polynucleotidyl transferases. Science (Washington, D.C.) 1994, 266:1981-1986.
17. Bujacz G., Alexandratos J., Qing Z.L., Clement-Mella C., Wlodawer A. The catalytic domain of human immunodeficiency virus integrase: ordered active site in the F185H mutant. FEBS Lett. 1996, 398:175-178.
18. Bujacz G., Jaskolski M., Alexandratos J., Wlodawer A., Merkel G., Katz R.A., Skalka A.M. The catalytic domain of avian sarcoma virus integrase: conformation of the active-site residues in the presence of divalent cations. Structure 1996, 4:89-96.
19. Chen J.C., Krucinski J., Miercke L.J., Finer-Moore J.S., Tang A.H., Leavitt A.D., Stroud R.M. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc. Natl. Acad. Sci. USA 2000, 97:8233-8238.
20. Goldgur Y., Dyda F., Hickman A.B., Jenkins T.M., Craigie R., Davies D.R. Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. Proc. Natl. Acad. Sci. USA 1998, 95:9150-9154.
21. Maignan S., Guilloteau J.P., Zhou-Liu Q., Clement-Mella C., Mikol V. Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases. J. Mol. Biol. 1998, 282:359-368.
22. Goldgur Y., et al. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc. Natl. Acad. Sci. USA 1999, 96:13040-13043.
23. Greenwald J., Le V., Butler S.L., Bushman F.D., Choe S. The mobility of an HIV-1 integrase active site loop is correlated with catalytic activity. Biochemistry 1999, 38:8892-8898.
24. Molteni V., Greenwald J., Rhodes D., Hwang Y., Kwiatkowski W., Bushman F.D., Siegel J.S., Choe S. Identification of a small-molecule binding site at the dimer interface of the HIV integrase catalytic domain. Acta Crystallogr. Sect. D 2001, 57:536-544.
25. Cherepanov P., Ambrosio A.L., Rahman S., Ellenberger T., Engelman A. Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc. Natl. Acad. Sci. USA 2005, 102:17308-17313.
26. Lubkowski J., et al. Structure of the catalytic domain of avian sarcoma virus integrase with a bound HIV-1 integrase-targeted inhibitor. Proc. Natl. Acad. Sci. USA 1998, 95:4831-4836.
27. Chen Z., et al. X-ray structure of simian immunodeficiency virus integrase containing the core and C-terminal domain (residues 50-293) - an initial glance of the viral DNA binding platform. J. Mol. Biol. 2000, 296:521-533.
28. Yang Z.N., Mueser T.C., Bushman F.D., Hyde C.C. Crystal structure of an active two-domain derivative of Rous sarcoma virus integrase. J. Mol. Biol. 2000, 296:535-548.
29. Hare S., Shun M., Gupta S., Valkov E., Engelman A., Cherepanov P., Ross S. A novel co-crystal structure affords the design of gain-of-function lentiviral integrase mutants in the presence of modified PSIP1/LEDGF/p75. PLoS Pathog. 2009, 5:e1000259.
30. Wang J.Y., Ling H., Yang W., Craigie R. Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. EMBO J. 2001, 20:7333-7343.
31. Cai M.L., Huang Y., Caffrey M., Zheng R.L., Craigie R., Clore G.M., Gronenborn A.M. Solution structure of the His12→Cys mutant of the N-terminal zinc binding domain of HIV-1 integrase complexed to cadmium. Protein Sci. 1998, 7:2669-2674.
32. Cai M.L., Zheng R.L., Caffrey M., Craigie R., Clore G.M., Gronenborn A.M. Solution structure of the N-terminal zinc binding domain of HIV-1 integrase. Nat. Struct. Biol. 1997, 4:839-840.
33. Eijkelenboom A.P., van den Ent F.M., Wechselberger R., Plasterk R.H., Kaptein R., Boelens R. Refined solution structure of the dimeric N-terminal HHCC domain of HIV- 2 integrase. J. Biomol. NMR 2000, 18:119-128.
34. Eijkelenboom A., Sprangers R., Hard K., Lutzke R.A.P., Plasterk R.H.A., Boelens R., Kaptein R. Refined solution structure of the C-terminal DNA-binding domain of human immunovirus-1 integrase. Proteins Struct. Funct. Genet. 1999, 36:556-564.
35. Lodi P.J., Ernst J.A., Kuszewski J., Hickman A.B., Engelman A., Craigie R., Clore G.M., Gronenborn A.M. Solution structure of the DNA binding domain of HIV-1 integrase. Biochemistry 1995, 34:9826-9833.
36. Cherepanov P. LEDGF/p75 interacts with divergent lentiviral integrases and modulates their enzymatic activity in vitro. Nucleic Acids Res. 2007, 35:113-124.
37. Cherepanov P., Devroe E., Silver P.A., Engelman A. Identification of an evolutionarily conserved domain in human lens epithelium-derived growth factor/transcriptional co-activator p75 (LEDGF/p75) that binds HIV-1 integrase. J. Biol. Chem. 2004, 279:48883-48892.
38. Cherepanov P., Maertens G., Proost P., Devreese B., Van Beeumen J., Engelborghs Y., De Clercq E., Debyser Z. HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J. Biol. Chem. 2003, 278:372-381.
39. Engelman A., Cherepanov P., Finlay B. The lentiviral integrase binding protein LEDGF/p75 and HIV-1 replication. PLoS Pathog. 2008, 4:e1000046.
40. Poeschla E.M. Integrase, LEDGF/p75 and HIV replication. Cell Mol. Life Sci. 2008, 65:1403-1424.
41. Michel F., Crucifix C., Granger F., Eiler S., Mouscadet J.F., Korolev S., Agapkina J., Ziganshin R., Gottikh M., Nazabal A., Emiliani S., Benarous R., Moras D., Schultz P., Ruff M. Structural basis for HIV-1 DNA integration in the human genome, role of the LEDGF/P75 cofactor. EMBO J. 2009, 28:980-991.
42. Hare S., Di Nunzio F., Labeja A., Wang J., Engelman A., Cherepanov P. Structural basis for functional tetramerization of lentiviral integrase. PLoS Pathog. 2009, 5:e1000515.
43. Brass A.L., Dykxhoorn D.M., Benita Y., Yan N., Engelman A., Xavier R.J., Lieberman J., Elledge S.J. Identification of host proteins required for HIV infection through a functional genomic screen. Science 2008, 319:921-926.
44. Violot S., et al. The human polycomb group EED protein interacts with the integrase of human immunodeficiency virus type 1. J. Virol. 2003, 77:12507-12522.
45. Rakotobe D., Violot S., Hong S.S., Gouet P., Boulanger P. Mapping of immunogenic and protein-interacting regions at the surface of the seven-bladed beta-propeller domain of the HIV-1 cellular interactor EED. Virol. J. 2008, 5:32.
46. Morozov A., Yung E., Kalpana G.V. Structure-function analysis of integrase interactor 1/hSNF5L1 reveals differential properties of two repeat motifs present in the highly conserved region. Proc. Natl. Acad. Sci. USA 1998, 95:1120-1125.
47. Maroun M., et al. Inhibition of early steps of HIV-1 replication by SNF5/Ini1. J. Biol. Chem. 2006, 281:22736-22743.
48. Kalpana G.V., Marmon S., Wang W., Crabtree G.R., Goff S.P. Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5. Science 1994, 266:2002-2006.
49. Woodward C.L., Prakobwanakit S., Mosessian S., Chow S.A. Integrase interacts with nucleoporin NUP153 to mediate the nuclear import of human immunodeficiency virus type 1. J. Virol. 2009, 83:6522-6533.
50. Wilkinson T.A., Januszyk K., Phillips M.L., Tekeste S.S., Zhang M., Miller J.T., Le Grice S.F., Clubb R.T., Chow S.A. Identifying and characterizing a functional HIV-1 reverse transcriptase-binding site on integrase. J. Biol. Chem. 2009, 284:7931-7939.
51. Hehl E.A., Joshi P., Kalpana G.V., Prasad V.R. Interaction between human immunodeficiency virus type 1 reverse transcriptase and integrase proteins. J. Virol. 2004, 78:5056-5067.
52. Tasara T., Maga G., Hottiger M.O., Hubscher U. HIV-1 reverse transcriptase and integrase enzymes physically interact and inhibit each other. FEBS Lett. 2001, 507:39-44.
53. Shun M.C., et al. Identification and characterization of PWWP domain residues critical for LEDGF/p75 chromatin binding and human immunodeficiency virus type 1 infectivity. J. Virol. 2008, 82:11555-11567.
54. Levin A., Armon-Omer A., Rosenbluh J., Melamed-Book N., Graessmann A., Waigmann E., Loyter A. Inhibition of HIV-1 integrase nuclear import and replication by a peptide bearing integrase putative nuclear localization signal. Retrovirology 2009, 6:112.
55. Engelman A., Liu Y., Chen H.M., Farzan M., Dyda F. Structure-based mutagenesis of the catalytic domain of human immunodeficiency virus type 1 integrase. J. Virol. 1997, 71:3507-3514.
56. Lu R., Limon A., Devroe E., Silver P.A., Cherepanov P., Engelman A. Class II integrase mutants with changes in putative nuclear localization signals are primarily blocked at a postnuclear entry step of human immunodeficiency virus type 1 replication. J. Virol. 2004, 78:12735-12746.
57. McPherson A. Preparation and analysis of protein crystals 1982, John Wiley & Sons, New York.
58. Leslie A.G.W. Recent changes to the MOSFLM package for processing film and image plate data Joint CCP4+ESF-EAMCB. Newslett. Protein Crystallogr. 1992, 26.
59. Evans P. Scaling and assessment of data quality. Acta Crystallogr. D Biol. Crystallogr. 2006, 62:72-82.
60. Collaborative Computational Project Number 4. (1994). The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760-763.
61. Navaza J. AMoRe: an automated package for molecular replacement. Acta Crystallogr. A 1994, 50:157-163.
62. Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 2004, 60:2126-2132.
63. Adams P.D., et al. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr. D Biol. Crystallogr. 2002, 58:1948-1954.
64. Laskowski R.A., Moss D.S., Thornton J.M. Main-chain bond lengths and bond angles in protein structures. J. Mol. Biol. 1993, 231:1049-1067.
65. DeLano W.L. The PyMOL Molecular Graphics Systemed 2002, DeLano Scientific, Palo Alto, CA, USA.
66. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. The Protein Data Bank. Nucleic Acids Res. 2000, 28:235-242.
67. Wielens J., Crosby I.T., Chalmers D.K. A three-dimensional model of the human immunodeficiency virus type 1 integration complex. J. Comput. Aided Mol. Des. 2005, 19:301-317.
68. Ceccherini-Silberstein F., Malet I., D'Arrigo R., Antinori A., Marcelin A.G., Perno C.F. Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev. 2009, 11:17-29.
69. Ovenden S.P., et al. Globoidnan A: a lignan from Eucalyptus globoidea inhibits HIV integrase. Phytochemistry 2004, 65:3255-3259.
70. Brown G.M., Levy H.A. Sucrose: precise determination of crystal and molecular structure by neutron diffraction. Science 1963, 141:921-923.
71. Immel S., Lichtenthaler F.W. Molecular modeling of saccharides, 7. The conformation of sucrose in water: a molecular dynamics approach. Liebigs Annalen 1995, 1995:1925-1937.
72. Duker J.M., Serianni A.S. (13C)-substituted sucrose: 13C-1H and 13C-13C spin coupling constants to assess furanose ring and glycosidic bond conformations in aqueous solution. Carbohydr. Res. 1993, 249:281-303.
73. Skov L.K., Mirza O., Sprogoe D., Dar I., Remaud-Simeon M., Albenne C., Monsan P., Gajhede M. Oligosaccharide and sucrose complexes of amylosucrase. Structural implications for the polymerase activity. J. Biol. Chem. 2002, 277:47741-47747.
74. Bourne Y., Rouge P., Cambillau C. X-ray structure of a (alpha-Man(1-3)beta-Man(1-4)GlcNAc)-lectin complex at 2.1-A resolution. The role of water in sugar-lectin interaction. J. Biol. Chem. 1990, 265:18161-18165.
75. Zhou T., et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007, 445:732-737.
76. Kerfeld C.A., Sawaya M.R., Brahmandam V., Cascio D., Ho K.K., Trevithick-Sutton C.C., Krogmann D.W., Yeates T.O. The crystal structure of a cyanobacterial water-soluble carotenoid binding protein. Structure 2003, 11:55-65.
77. Connolly M.L. Solvent-accessible surfaces of proteins and nucleic acids. Science (Washington, D.C.) 1983, 221:709-713.
78. Lin Z., et al. Chicoric acid analogues as HIV-1 integrase inhibitors. J. Med. Chem. 1999, 42:1401-1414.